EHA 2024 – Nitin Jain
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationNitin Jain elucidates the promising outcomes of the time-limited triplet therapy with pirtobrutinib, venetoclax, and obinutuzumab in first-line CLL treatment and addresses future challenges in clinical implementation. He shares recent advances in the development of more potent BTK inhibitors and depicts his personal highlights from this year’s EHA congress.
Here is the full EHA 2024 report.
More posts
Preface – EHA 2024
At the European Hematology Association (EHA) congress held in Madrid, Spain, and virtually from 13th–16th June 2024, world-leading experts from 150 countries presented cutting-edge research and clinical trials. This year, we witnessed significant advancements in the treatment of chronic lymphocytic leukemia (CLL).